Imatinib mesylate (STI 571, Glivec)
-
Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
Ladislav Chrobák, Jaroslava Voglová
2003, Vol. 46, Issue 3, pp. 85-89
Ladislav Chrobák, Jaroslava Voglová